Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sanergy-group-ltd" target="_blank" data-smartkarma-citation="entities:40079:1" rel="noopener">Sanergy (2459 HK)</a>, a graphite electrode manufacturer, was added to the MSCI Small-Cap Index on 30th August; and was due to enter the Hang Seng Composite Index on 9th September.</li>
<li>However, the SFC <a href="https://www.hkexnews.hk/listedco/listconews/sehk/2024/0902/2024090202067.pdf" target="_blank" rel="noopener">announced</a> a concentration warning on the 2nd September. Shares promptly cratered ~98% yesterday (the 3rd September). Expect the HSCI inclusion to now be yanked.</li>
<li>This Sanergy debacle should refocus investors on other heavily concentrated stocks, such as <a href="https://www.smartkarma.com/entities/jinhai-medical-technology-limited" target="_blank" data-smartkarma-citation="entities:40641:1" rel="noopener">Jinhai Medical (2225 HK)</a>, in which <a href="https://www.smartkarma.com/entities/gofintech-innovation-ltd" target="_blank" data-smartkarma-citation="entities:4384:1" rel="noopener">GoFintech (290 HK)</a> (another heavily concentrated stock) has inexplicably been buying. </li>
</ul>



Sanergy (2459 HK), a graphite electrode manufacturer, was added to the MSCI Small-Cap Index on 30th August; and was due to enter the Hang Seng Composite Index on 9th September.
However, the SFC announced a concentration warning on the 2nd September. Shares promptly cratered ~98% yesterday (the 3rd September). Expect the HSCI inclusion to now be yanked.
This Sanergy debacle should refocus investors on other heavily concentrated stocks, such as Jinhai Medical (2225 HK), in which GoFintech (290 HK) (another heavily concentrated stock) has inexplicably been buying. 


GoFinTech (290 HK)/Jinhai Medical (2225 HK): Double Bubble Trouble

GoFintech Innovation

GoFinTech (290 HK)/Jinhai Medical (2225 HK): Double Bubble Trouble